|
Market Closed -
Nasdaq
21:00:00 18/02/2026 GMT
|
5-day change
|
1st Jan Change
|
|
332.68 USD
|
+0.02%
|
 |
+3.23%
|
-16.34%
|
|
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing
|
MT
| |
01-14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing
|
MT
| |
01-14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing
|
MT
| |
01-14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,008,766, According to a Recent SEC Filing
|
MT
| |
01-14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,475,157, According to a Recent SEC Filing
|
MT
| |
01-14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,929, According to a Recent SEC Filing
|
MT
| |
01-13 |
Alnylam Pharmaceuticals CEO on Development Goals, Profitability
|
MT
| |
01-08 |
Praxis Precision Medicines, Inc. Announces Management and Committees Changes
|
CI
| |
12-10 |
Elevance Health Announces Appointment of Amy Schulman as Independent Director, Effective January 12, 2026
|
CI
| |
12-03 |
Alnylam Pharmaceuticals Announces Changes to Board of Directors
|
CI
| |
12-03 |
Alnylam Pharmaceuticals announces changes to board of directors
|
RE
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,692,062, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,103,451, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $635,126, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
|
MT
| |
02/09/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,557,649, According to a Recent SEC Filing
|
MT
| |
19/08/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
|
MT
| |
19/08/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,163,346, According to a Recent SEC Filing
|
MT
| |
19/08/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,030,727, According to a Recent SEC Filing
|
MT
| |
19/08/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
|
MT
| |
19/08/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,299,746, According to a Recent SEC Filing
|
MT
| |
18/06/25 |
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
